Intravenous immunoglobulin for dysphagia of inclusion body myositis

Chérìn, P.; Pelletier, S.; Teixeira, Antônio R. L.; Laforêt, Pascal; Simón, A. Prós; Herson, S.; Eymard, B.

doi:10.1212/wnl.58.2.326

Cited by 110 publications

(66 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The aim of the myotomy is to remove the impaired UES relaxation, which is not overcome by decreased PP. Indeed, myotomy has shown to be useful in improving dysphagia associated with UES hyperactivities in s-IBM, however, other therapies, such as intravenous immunoglobulin [16] or botulinum toxin A [17], and balloon dilation have been employed for s-IBM patients with dysphagia.…”

Section: Discussionmentioning

confidence: 99%

A dysphagia study in patients with sporadic inclusion body myositis (s-IBM)

et al. 2011

View full text Add to dashboard Cite

The nature of the swallowing impairment in patients with sporadic inclusion body myositis (s-IBM) has not been well characterized. In this study, we examined ten consecutive s-IBM patients using videofluoroscopy (VF) and computed pharyngoesophageal manometry (CPM). The patients were divided into two groups: patients with complaint and without complaint of dysphagia. VF results indicated pharyngeal muscle propulsion (PP) at the hypopharyngeal and upper esophagus sphincter (UES) in all s-IBM patients. Patients without complaint of dysphagia showed a mild degree of PP, whereas a severe form of PP was observed in patients with complaint of dysphagia. CPM revealed that negative pressure during UES opening was not observed in the s-IBM patients with complaint of dysphagia. Incomplete opening and PP at the UES were observed in all s-IBM patients. These results indicate that the dysphagic processes occur subclinically in s-IBM patients who may not report swallowing impairments.

show abstract

Section: Discussionmentioning

confidence: 99%

A dysphagia study in patients with sporadic inclusion body myositis (s-IBM)

et al. 2011

View full text Add to dashboard Cite

show abstract

“…In controlled prospective studies, IVIG had improved dysphagia [ 45,46,47] , but had no impact in increasing of the limb strength [47][48][49][50].…”

Section: Intravenous Immunoglobulin (Ivig)mentioning

confidence: 95%

Current pharmacological treatment of idiopathic inflammatory myopathies

Fasano

Alves²,

Isenberg

2016

Expert Review of Clinical Pharmacology

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies are uncommon and heterogeneous disorders. Their classification is based on distinct clinicopathologic features. Although idiopathic inflammatory myopathies share some similarities, different subtypes may have variable responses to therapy, so it is very important to distinguish the correct subtype.There are few randomised, double blind placebo controlled studies to support the current treatment.High dose corticosteroids continue to be the first line therapy and other immunosupressive drugs are used in refractory cases, as well as steroid-sparing agents.Some novel therapeutic approaches have emerged as potential treatment including tacrolimus, intravenous immunoglobulin and rituximab, following good outcomes reported in case studies.However, more randomised controlled trials are needed.This review considers the current and the potential future therapies for inflammatory myopathies.

show abstract

“…73 Intravenous immune globulin has been found to be ineffective in controlled trials but may transiently help some patients, especially those with dysphagia. 74,75 Alemtuzumab may provide short-term stabilization, 76 but a controlled study is needed. Treatment with anakinra has also not been successful.…”

Section: Tr E Atment Of Der M At Om Yositis Polym Yositis a Nd Necrmentioning

confidence: 99%